Press release from Companies
Published: 2024-02-23 08:35:35
Copenhagen, Denmark, 23 February 2024 - Today is the first day of the subscription period in Curasight A/S’s ("Curasight" or the "Company" – TICKER: CURAS) new issue of shares with preferential rights for the Company's existing shareholders of up to DKK 51.2 million before transaction costs (the "Rights Issue"), which was resolved by the Board of Directors on 13 February 2024.
Summary of the Rights Issue For complete terms and conditions for the Rights Issue, please refer to the information memorandum ("Information Memorandum") established by the Board of Directors in connection with the Rights Issue according to the rules of Spotlight Stock Market, and which was published on 22 February 2024. The Information Memorandum is available on the Company's, Nordic Issuing AB's and Redeye AB's respective websites (www.curasight.com, www.nordic-issuing.se, www.redeye.se). Subscription forms are available on the Company's, Nordic Issuing AB’s, and Redeye AB's respective websites. Timetable for the Rights Issue Advisors Redeye AB is acting as a financial advisor to Curasight. DLA Piper Denmark Advokatpartnerselskab is acting as the legal adviser of Curasight. VP Euronext Securities A/S is the Company’s issuing agent and Nordic Issuing is acting as the settlement agent. For more information regarding Curasight, please contact: Ulrich Krasilnikoff, CEO Phone: +45 22 83 01 60 E-mail: uk@curasight.com
21 February – 5 March 2024
Trading in subscription rights
23 February – 7 March 2024
Subscription period
23 February until the Rights Issue is registered with the Danish Business Authority
Trading in temporary shares
Around 12 March 2024
Estimated publication of the outcome in the Rights Issue